The absence of molecular amplification in proteomics and metabolomics means that researchers rely heavily on sensitive detection of a biomarker during analytical separation. In recent years, LC performance has been the limiting factor in such experiments as the incremental improvement of conventional columns stalls. 

Based on top-level academic research demonstrating the effects of order and disorder in particulate-based separation systems, PharmaFluidics introduces a new generation of chromatography columns. The company’s know-how is the design and manufacturing of miniaturized separation columns by silicon micromachining. The perfect order in the stationary phase leads to unique benefits in terms of performance, reproducibility and robustness.

PharmaFluidics was founded in 2010 as a spin-off from the University of Brussels (VUB). The first external funding was raised in 2014, followed by additional capital increases in 2016 and 2018 from experienced venture capital investors. Sales of the µPACTM columns were launched in 2017, and the company continued to build its portfolio based on the pillar array technology.  In November 2021, Thermo Fisher Scientific announced the acquisition of Pharmafluidics.

With offices in Ghent, PharmaFluidics is located at the heart of the Flanders life sciences valley. This biotech hub features a mix of world-renowned universities, knowledge centers and biotech companies, giving the company direct access to talent opportunities and a network of thriving companies.